FIELD: medicine.
SUBSTANCE: invention refers to an oral composition marking procedure. A marking procedure involves surface distribution of a discolouring oxide and laser scanning of said oral composition surface with wave lengths 200 nm to 1100 nm and average force 0.1 V to 50 V in an interval whereat said composition surface is almost non-etched to agglomerate discolouring oxide particles to induce discoloration. The discolouring oxide applied in the given invention represents titanium dioxide, a yellow iron oxide (III) or red iron oxide (III).
EFFECT: marking procedure is high-yield and ensures the easy-to-identify oral compositions, such as drugs and foodstuff with no quality damage.
24 cl, 4 dwg, 4 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL FORMULATIONS OF HIF HYDROXYLASE INHIBITORS | 2014 |
|
RU2681304C2 |
| NOVEL INK COMPOSITION | 2011 |
|
RU2563763C1 |
| CARBIDE, NITRIDE AND SILICIDE REINFORCING AGENTS FOR LASER ABSORPTION | 2019 |
|
RU2770659C2 |
| STABLE PERORAL GEL-FORMING PHARMACEUTICAL COMPOSITION, METHOD FOR IT PREPARING, METHOD FOR PREVENTION ALTERATION IN MEDICINAL AGENT RELEASING, METHOD FOR ENHANCEMENT OF PHYSICAL STABILITY OF PERORAL COMPOSITION | 2000 |
|
RU2220715C2 |
| STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING LEVOCETIRIZINE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND MONTELUKAST OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2013 |
|
RU2614382C2 |
| COLOUR MARKING WITH LASER | 2004 |
|
RU2356741C2 |
| STABLE PERORAL SOLID COMPOSITION OF MEDICINAL PREPARATION | 2004 |
|
RU2284819C2 |
| MODIFIED RELEASE PHARMACEUTICAL COMPOSITION | 2009 |
|
RU2495666C2 |
| ADMINISTRATION OF RENIN INHIBITORS FOR PREVENTION OR TREATMENT OF DIASTOLIC DYSFUNCTION OR DIASTOLIC HEART FAILURE | 2005 |
|
RU2407523C2 |
| LAMINATION OF AMMONIUM OCTAMOLYBDATE (AOM) | 2012 |
|
RU2641735C2 |
